Innovative therapeutics

Investors/
Media

Welcome to BioMarin’s Investor Relations & Media Page

We’ve brought together a variety of information in one location to better assist you in your efforts to research and develop news articles and learn about our company.

BioMarin Pharmaceutical Inc. was founded in 1997, and since July 1999 the company's common stock has been traded on the Nasdaq National Market under the ticker symbol BMRN. BioMarin's policy is to fully comply with all rules put forth by the Securities and Exchange Commission and the Nasdaq National Market. For misplaced stock certificates, please contact our transfer agent directly.

Recent News
Jul 16, 2019

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday,...

Jul 9, 2019

BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in providing therapies for rare genetic diseases, today announced the appointment of pharmaceutical veteran and former Johnson & Johnson...

Jul 8, 2019

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that based on recent meetings with health authorities in the U.S. and Europe, the company plans to submit marketing applications to both...

Events & Presentations
Thursday, June 13, 2019
10:00am - 11:00am PDT

Jean-Jacques Bienaime, Chairman and CEO Hank Fuchs, President, Worldwide R&D


Stock Quote
NASDAQBMRN
BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU, LEMS

Products

Palynziq™
Brineura™
Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information